China Cuts Price of Cancer, Immune Drugs to Lower Patient Burden
This article is for subscribers only.
China cut the maximum retail prices for some cancer, immune and blood system drugs by an average of 17 percent, the country’s top planning agency said.
“Oncology, immune and blood system drugs are costly and have a greater impact on patients, so lowering their prices can effectively reduce the burden” on patients, the National Development and Reform Commission said in a statement posted on its website today.